Source

Commission Implementing Regulation (EU) 2023/2592 of 21 November 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-naphthylacetamide, 1-naphthylacetic acid, 2-phenylphenol (incl. its salts such as sodium salt), 8-hydroxyquinoline, amidosulfuron, bifenox, dicamba, difenoconazole, diflufenican, dimethachlor, esfenvalerate, etofenprox, fenoxaprop-P, fenpropidin, fenpyrazamine, fluazifop P, lenacil, napropamide, nicosulfuron, paraffin oils, paraffin oil, penconazole, picloram, prohexadione, spiroxamine, sulphur, tetraconazole and tri-allate

Implementing Regulation (EU) 2023/2592 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows: 1. Part A is amended as follows: (1) in the sixth column, expiration of approval, of row 169, Amidosulfuron, the date is replaced by ‘15 August 2025’; (2) in the sixth column, expiration of approval, of row 170, Nicosulfuron, the date is replaced by ‘31 March 2027’; (3) in the sixth column, expiration of approval, of row 172, Dicamba, the date is replaced by ‘31 March 2027’; (4) in the sixth column, expiration of approval, of row 173, Difenoconazole, the date is replaced by ‘15 March 2026’; (5) in the sixth column, expiration of approval, of row 176, Lenacil, the date is replaced by ‘15 August 2025’; (6) in the sixth column, expiration of approval, of row 178, Picloram, the date is replaced by ‘15 February 2028’; (7) in the sixth column, expiration of approval, of row 180, Bifenox, the date is replaced by ‘31 March 2027’; (8) in the sixth column, expiration of approval, of row 181, Diflufenican, the date is replaced by ‘15 January 2026’; (9) in the sixth column, expiration of approval, of row 182, Fenoxaprop-P, the date is replaced by ‘15 August 2025’; (10) in the sixth column, expiration of approval, of row 183, Fenpropidin, the date is replaced by ‘15 May 2027’; (11) in the sixth column, expiration of approval, of row 284, Dimethachlor, the date is replaced by ‘15 October 2026’; (12) in the sixth column, expiration of approval, of row 285, Etofenprox, the date is replaced by ‘31 March 2027’; (13) in the sixth column, expiration of approval, of row 287, Penconazole, the date is replaced by ‘15 October 2026’; (14) in the sixth column, expiration of approval, of row 288, Tri-allate, the date is replaced by ‘31 March 2027’; (15) in the sixth column, expiration of approval, of row 292, Sulphur, the date is replaced by ‘15 April 2025’; (16) in the sixth column, expiration of approval, of row 293, Tetraconazole, the date is replaced by ‘31 March 2027’; (17) in the sixth column, expiration of approval, of row 294, Paraffin oils, the date is replaced by ‘31 March 2027’; (18) in the sixth column, expiration of approval, of row 295, Paraffin oil, the date is replaced by ‘15 August 2025’; (19) in the sixth column, expiration of approval, of row 299, 2-phenylphenol (incl. its salts such as sodium salt), the date is replaced by ‘15 November 2027’; (20) in the sixth column, expiration of approval, of row 310, Napropamide, the date is replaced by ‘31 March 2027’. 2. Part B is amended as follows: (1) in the sixth column, expiration of approval, of row 6, Prohexadione, the date is replaced by ‘31 May 2026’; (2) in the sixth column, expiration of approval, of row 7, Spiroxamine, the date is replaced by ‘31 May 2026’; (3) in the sixth column, expiration of approval, of row 12, 1-naphthylacetamide, the date is replaced by ‘31 May 2026’; (4) in the sixth column, expiration of approval, of row 13, 1-naphthylacetic acid, the date is replaced by ‘31 May 2026’; (5) in the sixth column, expiration of approval, of row 15, Fluazifop P, the date is replaced by ‘31 May 2026’; (6) in the sixth column, expiration of approval, of row 18, 8-hydroxyquinoline, the date is replaced by ‘31 December 2024’; (7) in the sixth column, expiration of approval, of row 25, Fenpyrazamine, the date is replaced by ‘31 May 2026’. 3. In Part E: in the sixth column, expiration of approval, of row 2, Esfenvalerate, the date is replaced by ‘ 31 May 2026 ’.

Other acts of the same type

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview